Pharma BD Deal Intelligence
A $8.4B acquisition that gave Alexion the rare-disease enzyme therapy Kanuma (sebelipase alfa) via Synageva. The deal expanded Alexion's ultra-rare disease portfolio beyond Soliris, though the outcome trailed the announcement-day enthusiasm.
Alexion is paying $8.4 billion to acquire Synageva, one of the largest premiums paid to any company over $5 billion in market cap since 1995, for access to a…
Alexion acquired Synageva BioPharma for $8.4B for Kanuma (sebelipase alfa).
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Alexion acquired Synageva BioPharma for $8.4B for Kanuma (sebelipase alfa).
Kanuma (sebelipase alfa) is the only FDA-approved therapy for lysosomal acid lipase (LAL) deficiency — a Wolman disease / cholesteryl ester storage disease (CESD) spectrum. The competitive landscape is effectively empty within the direct MOA class and shaped by supportive care and transplant. LAL enzyme replacement (direct MOA): sebelipase alfa (Kanuma, Alexion/AstraZeneca Rare Disease) is the sole approved ERT — FDA approval Dec 2015, EMA approval Sept 2015. No competing recombinant LAL product is in clinical development. Gene therapy (investigational): AAV-based LIPA gene therapy candidates at academic centers (e.g., preclinical programs) but none in registrational trials. Supportive lipid management (adjunctive, different MOA class): statins — atorvastatin (Lipitor, generic), rosuvastatin (Crestor, generic) — and ezetimibe (Zetia, Merck; generic) are used to manage dyslipidemia in CESD but do not address underlying LAL deficiency. Hematopoietic stem cell transplant (procedural alternative): historically attempted in infantile Wolman disease with high mortality — now largely replaced by Kanuma per NIH/NORD guidance. Dietary management: low-fat diet and medium-chain triglyceride supplementation. For a commercial lead, Kanuma has a clean monopoly MOA franchise; ultra-rare prevalence (~1:40,000-300,000) and single-indication ERT positioning make the threat profile low but the patient identification lever critical.
SBC-103 (rhNAGLU) was an investigational recombinant N-acetyl-alpha-glucosaminidase enzyme replacement therapy for Mucopolysaccharidosis IIIB (MPS IIIB, Sanfilippo syndrome type B). No FDA-approved disease-modifying therapy exists for MPS IIIB; the landscape is defined by investigational modalities. Enzyme replacement therapy (direct MOA): tralesinidase alfa (BMN 250, BioMarin) — intracerebroventricular rhNAGLU fusion in Phase I/II, granted Regenerative Medicine Advanced Therapy designation; Allievex Corporation took over the AX 250 program after BioMarin divested. SBC-103 IV rhNAGLU was discontinued by Alexion in 2017 after Phase I/II results. Gene therapy (competing MOA class): LYS-SAF302 (Lysogene/Sanofi) — AAVrh.10-NAGLU intracerebral gene therapy, Phase II/III AAVANCE results released 2022; ABO-101 (Abeona Therapeutics) AAV9-NAGLU Phase I/II (program discontinued post-strategic review). Substrate reduction therapy: genistein investigational; no approved SRT for MPS IIIB. Hematopoietic stem cell transplant: limited efficacy for CNS disease in MPS IIIB, per NIH/NORD guidance. Supportive care: multidisciplinary symptomatic management. For a commercial lead, MPS IIIB is an ultra-rare pediatric neurodegenerative disease (<1:200,000 births) with no approved therapy; the historical and competitive assets (BMN 250, LYS-SAF302, ABO-101) face high development risk and narrow ERV economics.
Alexion acquired Synageva at $230/share to gain Kanuma for LAL deficiency. CEO projected billion-dollar potential.
Kanuma approved as first treatment for lysosomal acid lipase deficiency. Regulatory step in Alexion Pharmaceuticals's acquisition process for Synageva BioPharma.
Revenue of $29M vs $1B projected peak. Ultra-rare patient population severely limited commercial upside.
Alexion discontinued SBC-103 from Synageva, taking $85M impairment charge. Part of Alexion Pharmaceuticals's $8.4B deal to acquire Synageva BioPharma.
Massively Overpaid for Ultra-Niche Asset. Assessment of Alexion Pharmaceuticals's $8.4B acquisition of Synageva BioPharma and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Alexion Pharmaceuticals Inc. / Synageva BioPharma (this deal) | 2015 | $8.4B | 36 |
| Alexion Pharmaceuticals Inc. / Wilson Therapeutics AB | 2018 | $855M | 20 |
| Alexion Pharmaceuticals Inc. / Syntimmune, Inc. | 2018 | $1.2B | 14 |
| Alexion Pharmaceuticals Inc. / Portola Pharmaceuticals, Inc. | 2020 | $1.4B | — |
| Alexion Pharmaceuticals Inc. / Achillion Pharmaceuticals, Inc. | 2019 | $1.2B | — |
| Shire plc / Dyax Corp. | 2016 | $5.9B | 89 |
| Horizon Pharma plc / Hyperion Therapeutics, Inc. | 2015 | $1.1B | 79 |
← Browse all deals · How we score deals
More: 2015 deals · Alexion Pharmaceuticals Inc. deals · Rare Disease deals